These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 35558166)
21. Brexanolone for the treatment of patients with postpartum depression. Morrison KE; Cole AB; Thompson SM; Bale TL Drugs Today (Barc); 2019 Sep; 55(9):537-544. PubMed ID: 31584571 [TBL] [Abstract][Full Text] [Related]
22. Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster resilience. Lüscher B; Möhler H F1000Res; 2019; 8():. PubMed ID: 31275559 [TBL] [Abstract][Full Text] [Related]
23. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Meltzer-Brody S; Colquhoun H; Riesenberg R; Epperson CN; Deligiannidis KM; Rubinow DR; Li H; Sankoh AJ; Clemson C; Schacterle A; Jonas J; Kanes S Lancet; 2018 Sep; 392(10152):1058-1070. PubMed ID: 30177236 [TBL] [Abstract][Full Text] [Related]
24. Brexanolone For Postpartum Depression: A Novel Approach and a Call for Comprehensive Postpartum Care. Jarman AF; MacLean JV; Barron RJ; Wightman RS; McGregor AJ Clin Ther; 2020 Jan; 42(1):231-235. PubMed ID: 31910998 [TBL] [Abstract][Full Text] [Related]
25. Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used? Faden J; Citrome L Ther Adv Psychopharmacol; 2020; 10():2045125320968658. PubMed ID: 33224470 [TBL] [Abstract][Full Text] [Related]
26. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders. Walkery A; Leader LD; Cooke E; VandenBerg A Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503 [TBL] [Abstract][Full Text] [Related]
27. Novel neurosteroid therapeutics for post-partum depression: perspectives on clinical trials, program development, active research, and future directions. Patterson R; Balan I; Morrow AL; Meltzer-Brody S Neuropsychopharmacology; 2024 Jan; 49(1):67-72. PubMed ID: 37715106 [TBL] [Abstract][Full Text] [Related]
29. Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond. Zorumski CF; Paul SM; Covey DF; Mennerick S Neurobiol Stress; 2019 Nov; 11():100196. PubMed ID: 31649968 [TBL] [Abstract][Full Text] [Related]
30. Allopregnanolone: From molecular pathophysiology to therapeutics. A historical perspective. Paul SM; Pinna G; Guidotti A Neurobiol Stress; 2020 May; 12():100215. PubMed ID: 32435665 [TBL] [Abstract][Full Text] [Related]
31. Allopregnanolone-based treatments for postpartum depression: Why/how do they work? Walton N; Maguire J Neurobiol Stress; 2019 Nov; 11():100198. PubMed ID: 31709278 [TBL] [Abstract][Full Text] [Related]
33. Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression. Powell JG; Garland S; Preston K; Piszczatoski C Ann Pharmacother; 2020 Feb; 54(2):157-163. PubMed ID: 31476884 [No Abstract] [Full Text] [Related]
34. Biomarkers and treatments for mood disorders encompassing the neurosteroid and endocannabinoid systems. Pinna G J Neuroendocrinol; 2023 Feb; 35(2):e13226. PubMed ID: 36625096 [TBL] [Abstract][Full Text] [Related]